Dermatology

Latest News

Study Identifies Key Symptoms of Topical Steroid Withdrawal: Daily Dose / image credit: ©New Africa/AdobeStock
Study Identifies Key Symptoms of Topical Steroid Withdrawal: Daily Dose

February 5th 2025

Delgocitinib Effective in Adolescents with CHE in Phase 3 DELTA TEEN Trial / image credit Sonja Molin, MD  Queen’s University
Delgocitinib Effective in Adolescents with CHE in Phase 3 DELTA TEEN Trial

February 4th 2025

Tapinarof 1% Cream Significantly Improves Patient Reported Outcomes, Including Family QoL, in Atopic Dermatitis / image credit courtesy of OHSU
Tapinarof 1% Cream Significantly Improves Patient Reported Outcomes, Including Family QoL, in Atopic Dermatitis

January 27th 2025

Self-Reported Symptoms of Topical Steroid Withdrawal Identified in Study of Atopic Dermatitis
Self-Reported Symptoms of Topical Steroid Withdrawal Identified in Study of Atopic Dermatitis

January 23rd 2025

Latest CME Events & Activities

21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

February 8, 2025

View More

Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis

View More

Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making

View More

Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma

View More

Community Practice Connections™: 20th Annual International Symposium on Melanoma and Other Cutaneous Malignancies

View More

Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis

View More

Revolutionizing Atopic Dermatitis (RAD) Conference 2025

June 6-7, 2025

Register Now!

Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color

View More

Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach

View More

Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis

View More

Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis

View More

Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice

View More

‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis

View More

Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis

View More

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

View More

More News


Site Logo

Role of Anti–SS-A and Anti–SS-B Tests in Sjögren Diagnosis

December 31st 2006

I enjoyed the article by Kenneth H. Fye, MD, "Rheumatic Disease: How to Use theLab in the Workup" (CONSULTANT, March 2004, page 369). However, I foundthe following statement to be misleading: "Anti-SS-A and anti-SS-B determinationsare necessary to rule out Sjgren syndrome in patients with sicca complaints."If the results of these tests are negative, but Sjgren syndrome was initiallysuspected based on the history, labial biopsy is required. Many persons with thisdisease have negative antibody test results.Unfortunately, it often takes years before Sjgren syndrome is correctly diagnosedin most patients. This is usually because a health care provider rules it outbased on negative results of anti-SS-A and anti-SS-B tests.---- Paula Hochberg, ARNPSarasota, FlaYou are correct that negative results of tests foranti-SS-A and anti-SS-B antibodies do not ruleout Sjgren syndrome. Although the majorityof patients with this syndrome have these antibodies,a significant minority do not. If, in thislatter group of patients, Sjgren syndrome is strongly suspectedon clinical grounds, a minor salivary gland biopsyshould be considered. Biopsy is the most specific andsensitive test for Sjgren syndrome. Although a biopsy isnot required to make the diagnosis in every patient, thereare clearly those with negative tests for anti-SS-A andanti-SS-B in whom a biopsy is necessary to confirm suspectedSjgren syndrome. Thus, my statement shouldhave read instead, "Positive anti-SS-A and anti-SS-B determinationssupport a diagnosis of Sjgren syndrome inpatients with sicca complaints."---- Kenneth H. Fye, MDClinical Professor of MedicineRheumatology DivisionUniversity of California, San Francisco,School of Medicine

© 2025 MJH Life Sciences

All rights reserved.